Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole plus agomelatine for gastroesophageal reflux disease
ChiCTR2100045530Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rabeprazole and agomelatine in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Proportion of patients with at least 50% reduction in GERDQ score from baseline at week 12. Started Apr 2021; status: recruiting.
02
Drugs
rabeprazoleagomelatine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR2100045530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045530.